Acupuncture and Chinese Herbal Medicine During and After Chemotherapy:

By Dr. Erika F. Marie, DACM, LAc | Chiyu Integrative Health | Columbia, SC & Longmont, CO

Chemotherapy Treats Cancer, But Harms the Rest of the Body in the Process

Chemotherapy saves lives. That is not in question. But the drugs used to kill cancer cells are not precise weapons. Instead, they are broad-spectrum toxins. The collateral damage chemotherapeutic agents inflict on healthy tissue is extensive and well-documented. For many patients, the damage remains life-altering, even long after treatment ends.

Some damage, such as nausea and vomiting, is short term. Mucositis, raw, ulcerated tissue throughout the mouth and gastrointestinal tract, and bone marrow suppression that eliminates the body's ability to fight infection, are also typically short-term. Fatigue so profound it reshapes the rhythm of daily life, however, can stretch for months or even years.

Some damage is long-lasting, and can even be permanent: Peripheral neuropathy in the hands and feet. Cardiotoxicity that can damage the heart for years, even decades, after the last infusion. Pulmonary damage that can lead to life-threatening infection, persistent pneumonias, and multiple rounds of antibiotics. Kidney and liver damage that can be life-threatening or never fully heal. Gut dysbiosis known to increase risk of chronic graft-vs-host disease (CVHD) and a host of other issues, including a potentially increased risk for an autoimmune disorder later in life. An immune system that needs to be painstakingly rebuilt, with each necessary revaccination increasing systemic inflammation and potentially triggering additional system damages, such as CVHD.

Conventional oncology has effective tools for some of these — antiemetics for nausea, G-CSF for increasing white blood cell counts — but for many of the harms of chemotherapy, conventional medicine effectively says, “We’ll manage what we can, monitor what we can’t … but the rest you must endure. Here are more medications (each with known side effects and potential complications, resulting in what is known as a medication cascade) and a referral for PT/OT.”

In many ways, what appears callous is part of the design. Conventional specialists are trained in what is known medically as a reductionist model. This means that oncology, as a specialty, is laser-focused on eliminating cancer. It also means that oncology tends to regard the rest of the body’s systems as secondary to its primary mission: eliminate the cancer. The verbiage around cancer even encourages view “battling cancer” like a war. Collateral damage is expected. Sacrifices are necessary to win the victory. And patients are conditioned to accept their losses — perhaps their feet are excruciatingly painful and they have unexplained lymphedema and debilitating, demoralizing fatigue, but at least the cancer is gone, right?

Reductionism also happens in the field of non-malignant bone marrow transplantation (BMT), such as for pediatric allogenic BMT for Diamond-Blackfan Anemia. The primary job, or goal, of the transplantation specialist is to restore the bone marrow’s ability to produce healthy stem cells. Their job includes the oversight of prevention (if possible) and treatment (if possible) of side-effects and complications of transplant, such as chronic GVHD, Veno-Occlusive Disease (VOD), and Thrombotic Microangiopathy (TMA). Their achievements are measured with metrics such as 1-year, 2-year, and 5-year survival rates. They have limited tools when it comes to the pulmonary, immunologic, hormonal, and metabolic complications of transplant. Even severe complications, such as post-transplant reliance on immunoglobulins, are considered unfortunate but acceptable side effects, so long as the goal of independence from red blood cell products is achieved. Medicine, after all, is a moving target. It is a practice of self-improvement.

This is where integrative medicine has a genuinely important role to play. A growing and substantial body of clinical research (including a 2024 Journal of Clinical Oncology randomized controlled trial and multiple systematic reviews) supports the use of acupuncture and Chinese herbal medicine both during chemotherapy and in the recovery period that follows. The evidence covers not just well-known side-effects, but also some of the lesser-discussed organ-level harms that conventional oncology less effectively addresses.

This article covers what the research shows for patients of two separate populations: those undergoing standard chemotherapy for solid tumors and those undergoing the more intensive, marrow-ablative chemotherapy required for bone marrow transplantation (BMT), where the stakes and the biological demands of recovery are different in kind as well as degree.

Note Prior to Further Reading:

Everything in this article is intended as a framework for conversation with your oncology team and a qualified integrative practitioner — not as a self-treatment guide. The herbs documented here have real and studied herb-drug interactions with chemotherapy agents. Some herbs are contraindicated during active chemotherapy and appropriate only in the recovery period. Others can be used concurrently but require careful timing relative to infusion schedules, as well as the monitoring of liver and kidney health.

The formula-naming convention in this article is intentional. Where formula names are given, it is because the clinical research specifically studied that formula and the name is essential context. It does not constitute a prescription or recommendation for self-treatment. Chinese herbal formulas should only be prescribed by a formally educated Chinese herbal medicine provider who has reviewed your oncology plan, your current medications, and your individual presentation. Laboratory measures to monitor efficacy of medicines and health of organs are essential during active treatment phases.

Part One: Support During and After Standard Chemotherapy

Standard chemotherapy (including protocols for breast cancer, colorectal cancer, lung cancer, lymphoma, and most other solid tumors) produces a predictable constellation of side effects that respond well to integrative support.

Nausea and Vomiting (CINV)

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing side effects of cancer treatment, though it arguably is among the least concerning to oncologists, at least compared to cardio-toxicity and bone marrow suppression. (This changes when weight-loss is concerned, as involuntary weight-loss leads to less significantly worse cancer outcomes). Despite meaningful advances in antiemetic pharmacology, nausea and vomiting are still inadequately controlled for a significant proportion of patients. The concern is not trivial: severe CINV leads to dose reductions and treatment discontinuations that directly impact cancer outcomes.

Acupuncture for CINV has one of the strongest evidence bases in integrative oncology. The National Comprehensive Cancer Network (NCCN), the Society for Integrative Oncology (SIO), and the German Guideline Program in Oncology have all incorporated recommendations for acupuncture in the management of CINV.¹

The landmark clinical study in this space was published in the Journal of Clinical Oncology in 2024: a multicenter randomized controlled trial by Shen et al. testing the effect of adding electroacupuncture to standard triple antiemetic therapy (the current best-practice pharmaceutical regimen). True electroacupuncture produced significantly better control of nausea compared to sham electroacupuncture, with improvements in total control rates, "no significant nausea" rates, and nausea VAS scores across multiple outcome measures. The authors concluded electroacupuncture is safe, well-tolerated, and can serve as an option for enhanced prevention of CINV when combined with standard antiemetic regimens.²

This landmark result built on a body of earlier evidence, including a JAMA 2000 randomized controlled trial (also by Shen) showing that electroacupuncture significantly outperformed minimal needling and pharmacotherapy alone for emesis control in patients receiving highly emetogenic marrow-ablative chemotherapy.³ A 2023 systematic review and meta-analysis from the University of Zurich (Cancer Medicine) found that acupuncture added to usual care may increase complete control of both acute and delayed chemotherapy-induced vomiting.¹ A 2025 comprehensive meta-analysis — searching databases through December 2024 and including 17 randomized trials — confirmed that acupuncture reduces nausea and vomiting in cancer patients across chemotherapy, radiotherapy, and surgery contexts, with electroacupuncture and manual acupuncture showing the strongest effects.⁴

How It Works: The Mechanism of Acupuncture for CINV

The biological mechanisms of acupuncture analgesia for CINV are increasingly well-understood. The primary acupuncture point studied — PC6 (Neiguan) — has been confirmed to modulate the vagal-adrenal axis, a key pathway in both nausea perception and the autonomic regulation of gastric motility. A Nature-published study confirmed that electroacupuncture drives its anti-nausea effects in part through this vagal-adrenal pathway.⁴ Acupuncture at ST36 (Zusanli) additionally modulates serotonin pathways — specifically suppressing 5-HT3 receptor activity in the gut, which is the same receptor targeted by ondansetron and other pharmaceutical antiemetics. This serotonergic mechanism explains both why acupuncture works and why it can work additively with pharmaceutical antiemetics rather than redundantly.⁵

Cancer-Related Fatigue

Cancer-related fatigue (CRF) is the most common and one of the most debilitating symptoms experienced by people undergoing chemotherapy. Unlike normal tiredness, it is not relieved by rest, is disproportionate to activity, and involves multiple converging biological drivers: inflammatory cytokine elevation (IL-1β, IL-6, TNF-α), HPA axis dysregulation, mitochondrial dysfunction, disrupted sleep architecture, anemia from myelosuppression, and the direct neurotoxic effects of chemotherapy agents on the brain.

Multiple systematic reviews and meta-analyses support acupuncture for CRF. A review in the journal Cancer Medicine found acupuncture significantly reduced fatigue scores in cancer patients compared to usual care or sham control. The mechanisms align with what is documented in other pain and fatigue conditions: HPA axis normalization, cytokine reduction, endogenous opioid release, and restoration of sleep quality — each of which addresses a different driver of cancer fatigue simultaneously.⁶

From the herbal medicine side, the research on post-chemotherapy fatigue converges with the literature on myelosuppression (covered below), since the two are often inseparable. Herbal formulas that support bone marrow recovery and reduce oxidative stress also address the bioenergetic depletion underlying fatigue.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

CIPN affects approximately 68% of patients within the first month of chemotherapy and can persist for months to years. Platinum-based agents damage dorsal root ganglion neurons via DNA cross-linking; taxanes disrupt axonal transport by impairing microtubule dynamics. The result — numbness, tingling, burning, and pain in a stocking-glove distribution — has no approved pharmaceutical prevention and only limited treatment options.

The research on acupuncture and electroacupuncture for CIPN is covered in detail in the peripheral neuropathy article in this series. The key headlines: a 2025 dose-response meta-analysis of 11 RCTs and 740 cancer patients found acupuncture significantly improved both CIPN pain and quality of life, with optimal results at 8–12 sessions over 4–6 weeks. The ACUCIN trial, the first study to use nerve conduction studies as primary outcome, found acupuncture enhanced structural nerve regeneration measurable by NCS. Chinese herbal formulas addressed mitochondrial dysfunction, Schwann cell protection, and oxidative stress – vital for CIPN recovery. All of these approaches are most effective when begun as early as possible during or after chemotherapy, before potentially irreversible structural nerve damage accumulates.

Oral Mucositis: A Painful Side Effect that can lead to Complications

Oral mucositis — ulceration and inflammation of the mucosal lining of the mouth, throat, and esophagus — affects approximately 40% of patients receiving standard-dose chemotherapy and up to 80% of those receiving high-dose chemotherapy before BMT. It is not merely painful; it disrupts nutrition, increases infection risk, and frequently forces dose reductions or treatment delays that compromise cancer outcomes.

A 2022 systematic review and meta-analysis published in Frontiers in Pharmacology evaluated Chinese patent medicines for the prevention and treatment of radiotherapy- and chemotherapy-induced oral mucositis, finding that Chinese herbal formulas reduced mucositis severity, shortened healing time, and improved quality of life compared to standard care.⁷ A 2024 systematic review of natural products for radiotherapy-induced oral mucositis — including 36 clinical trials with 2,400 participants — found substantial efficacy across multiple natural product categories in reducing intensity, incidence, pain scores, and symptoms like xerostomia.⁸

A detailed survey of Chinese herbal treatment for chemotherapy-induced oral mucositis reviewed 18 clinical studies of single herbs, herb pairs, and multi-herb prescriptions, finding improvement rates for the herbal treatment groups consistently exceeding standard care controls. The molecular mechanisms identified include ROS reduction, anti-inflammatory cytokine suppression (particularly IL-6, a key driver of mucosal inflammation), antimicrobial effects, immunomodulation, and wound-healing pathway activation — all of which are relevant to the biological process of mucositis development and repair.⁹

A 2025 systematic review specifically evaluating acupuncture for radiation- and chemotherapy-induced oral mucositis, searching eight biomedical databases through July 2025, found that acupuncture modalities demonstrate both preventive and therapeutic efficacy for oral mucositis management. The mechanisms include local anti-inflammatory effects and immune modulation at the mucosal level.¹⁰‍ ‍

Cardiotoxicity: One of Chemotherapy's Most Serious Long-Term Harms

Cardiotoxicity is the second leading cause of morbidity and mortality in cancer survivors, second only to cancer recurrence itself. Up to 20% of adults undergoing cancer treatment experience cardiotoxicity, and 7–10% develop cardiomyopathy or heart failure.¹¹ Anthracyclines — including doxorubicin, daunorubicin, and epirubicin, used widely in breast cancer, lymphoma, sarcoma, and pediatric leukemia — are the most well-documented culprits, producing dose-dependent and potentially irreversible cardiac damage through multiple mechanisms: reactive oxygen species (ROS) generation and mitochondrial oxidative injury, cardiomyocyte apoptosis, disrupted calcium homeostasis, and in chronic exposure, autophagic dysfunction that allows damaged mitochondria to accumulate. Cardio-protection, therefore, is extremely vital where ever possible.

The only FDA-approved cardioprotective agent — dexrazoxane — is expensive, incompletely effective, and not widely used. Beta-blockers and ACE inhibitors offer modest benefit. This represents a genuine unmet clinical need, and Chinese herbal medicine has a growing body of mechanistic and clinical evidence addressing it.

A 2022 meta-analysis published in Medicine (the first study of its kind) analyzed 17 RCTs of 11 specific Chinese herbal formulas for preventing anthracycline-induced cardiotoxicity in cancer patients and concluded that Chinese herbal medicine is an effective and safe cardioprotective intervention.¹² A 2026 systematic analysis of 104 preclinical studies identified 65 TCM-derived natural compounds that protect against doxorubicin cardiotoxicity through six core pathways: oxidative stress and ferroptosis, apoptosis, inflammation and pyroptosis, mitochondrial homeostasis, autophagy, and endoplasmic reticulum stress, with Nrf2, SIRT1, mTOR, and AMPK identified as the central molecular hub nodes.¹³

Key compounds with documented cardioprotective mechanisms include compounds from Salvia miltiorrhiza (Dan Shen) — particularly tanshinone IIA and salvianolic acids. These compounds reduce doxorubicin-induced ROS, inhibit cardiomyocyte apoptosis via Bcl-2/Bax modulation, and protect mitochondrial function. Ginsenoside compounds reduce cardiac autophagy dysregulation induced by doxorubicin. Astragalus membranaceus extracts protect cardiac mitochondrial bioenergetics. While some of these herbs may be unfamiliar to Western cardiologists, they are not obscure or experimental compounds — they are well-characterized active herbal ingredients with centuries of use and decades of modern pharmacological study.¹¹˒¹²˒¹³

For acupuncture specifically, animal studies have demonstrated that electroacupuncture at point PC6 can prevent doxorubicin-induced cardiotoxicity by reducing nitric oxide generation driven by doxorubicin, suggesting a direct cardioprotective neuromodulatory mechanism alongside its established anti-nausea effects at the same point.¹¹

Bone Marrow Suppression: Supporting the Blood-Forming System

Myelosuppression, the suppression of bone marrow's blood-producing function, is one of the most clinically dangerous effects of chemotherapy. When white blood cell counts fall, infection risk rises dramatically. When platelet counts drop, bleeding risk increases. When red blood cell production is impaired, fatigue worsens. Severe myelosuppression can force dose reductions or treatment discontinuation that compromise cancer outcomes.

A systematic review of Chinese herbal medicine for chemo- and radiotherapy-induced myelosuppression found that herbal medicine significantly protected white blood cells from chemotherapy damage. This finding offers real clinical significance, since white blood cell recovery is the bottleneck for maintaining treatment intensity.¹⁴ A 2024 systematic review and meta-analysis of herbal extracts for chemotherapy-induced myelosuppression, searching six English and Chinese databases, found evidence supporting herbal extracts for mitigating myelosuppression, improving hematopoietic recovery, and reducing treatment-related complications.¹⁵

The formula Danggui Buxue Decoction (a classical two-herb combination for anemia) has been specifically studied for chemotherapy-induced myelosuppression. A 2023 pharmacological study found it alleviates bone marrow suppression by intervening in beta-hydroxybutyric acid metabolism and suppressing oxidative stress. Results of the study showed measurable improvements in blood cell counts across multiple cell lines in treated animals.¹⁶ This formula is also studied for post-BMT immune recovery (see Part Two).

Anorexia, Digestive Dysfunction, and Gut Lining Restoration

Chemotherapy disrupts gastrointestinal function through multiple mechanisms: direct mucosal damage of the intestines (the same process that causes mucositis extends throughout the gut lining), altered gut motility from neurotoxic effects on the enteric nervous system, and profound gut microbiome dysbiosis. The result is often a combination of anorexia, nausea, early satiety, bloating, diarrhea, and nutritional depletion that makes recovery significantly more difficult.

Acupuncture at ST36 (Zusanli) has been repeatedly studied for gastrointestinal function in the oncology context. A systematic review of acupuncture for postoperative gastrointestinal dysfunction in colorectal cancer found significant evidence supporting acupuncture for restoring gut motility and normalizing gastrointestinal function after surgery and chemotherapy.¹⁷ The mechanism operates through vagal nerve modulation, enteric serotonin regulation, and anti-inflammatory cytokine reduction in the gut wall, all of which address different aspects of chemotherapy-induced GI disruption.

On the herbal medicine side, one of the most clinically relevant emerging areas is the interaction between Chinese herbal compounds and the gut microbiome. Research published in multiple peer-reviewed journals has documented that Chinese herbal formulas reshape the gut microbial community after chemotherapy-induced dysbiosis. Chinese herbal formulas accomplish this feat in a number of ways: by enriching beneficial bacteria including Akkermansia muciniphila and lactic acid bacteria, suppressing pro-inflammatory bacterial populations, and restoring the short-chain fatty acid production (particularly butyrate) that is essential for intestinal barrier repair and immune function.¹⁸ This gut microbiome restoration has implications not just for digestive symptoms but for the downstream immune recovery that determines a patient's resilience after treatment. It also has enormous implications for reducing the risk and severity of chronic GVHD in bone marrow transplantation.

Part Two: Support for Bone Marrow Transplant (Marrow-Ablative Chemotherapy)

Bone marrow transplantation is a fundamentally greater magnitude of biological insult than standard chemotherapy. Whether autologous (the patient's own stem cells are returned after high-dose agents) or allogeneic (donor cells are infused), the conditioning regimen requires doses of chemotherapy or radiation designed to completely destroy the existing marrow, with the intent that the transplanted cells will repopulate it. There is no partial suppression. Instead, there is complete ablation or eradication of bone marrow, followed by a period of profound immune vulnerability during which the new marrow establishes itself. The level of immune vulnerability is extreme, requiring masking outdoors to avoid inhaling fungal spores, avoidance of dirt and soil, and near-total social isolation for at least six months but typically a year or more.

The side effects and risks of marrow-ablative conditioning are severe. They overlap significantly with standard chemotherapy but are more intense, more prolonged, and carry additional risks (particularly in allogenic BMT). These risks include both acute and chronic graft-versus-host disease (GVHD), more severe mucositis from the higher doses of chemotherapeutic agents, pulmonary complications, total hair loss, damage to hormonal and metabolic organs and pathways (including fertility loss), life-threatening damage to the liver and blood vessels for as long as the patient is on necessary immunosuppression, brain fog and neural changes, and a delicate reconstitution period where the immune system must be rebuilt, to include revaccination with all infant and childhood vaccines. To say that marrow-ablative conditioning causes widespread systemic inflammation and damage would be overstating the obvious. Yet, while inflammation is known to be a driving force in the development of debilitating disease, reducing the body’s oxidative and inflammatory burden in chemotherapy is not standard of care.

This oversight is where integrative medicines such as Chinese herbal medicine and acupuncture can offer a much-needed and outcome-changing level of support to both patients and transplant teams. During marrow-ablative conditioning, the stakes and need are proportionally greater than in standard conditioning, yet physician willingness to include adjunct care is narrower. There is significant worry about anything that might interfere with engraftment, either triggering GVHD or leading to an infectious overgrowth that cannot be contained. Typically, this translates to a tendency to refuse any intervention that has not yet undergone years of clinical trials. While understandable, this tendency is not often rooted in theory or understanding of the intervention or its mechanism of action. And present-day patients in need of transplant cannot wait years for trials. When simple, logical, and safe interventions are passed over, it is the patient who ultimately pays the price.

However, tides are turning. For example, leading transplant centers once forbade fresh fruit and vegetables and any product containing probiotics. Today, there is better understanding of the role fresh and fermented foods in health. Those same centers now encourage properly washed fresh fruits and vegetables as well as pasteurized yogurts and smoothies containing probiotic blends. (High-dose probiotics are still forbidden as a potential source of uncontrollable bacterial overgrowth).

Acknowledging the importance of whole-food nutrition and the gut microbiome are encouraging advancements, but there remains significant room for better outcomes with integrative care. The side-effects of chemotherapy, particularly in marrow-ablative regimens, remain awful: mucositis so severe that patients require opioid medications as well as the placement of nG tubes for feeding, and steroids required to stop GVHD and systemic immune responses. Even with the lesser-toxic chemotherapeutic agents such as treosulfan, chemotherapy for marrow-ablative conditioning is disastrous to the integrity of multiple organ systems and on systemic inflammatory levels.

This is where Chinese herbal medicine and acupuncture “fill the gap” in patient-centered care. Both Chinese herbal medicine and acupuncture have proven effects on reducing inflammation and reactive oxygen species (ROS) by modulating and neutralizing damaged mitochondria and cytokines, which aids in the healing of tissues and organs. In addition, Chinese herbal medicine and acupuncture have neurological and hormonal effects, calming cortisol, modulating from sympathetic (stressed) to parasympathetic (healing) states, releasing natural endorphins and dopamine, and instigating peristalsis.

One article cannot cover all of the ways in which these integrative medicines can “fill the gap” to improve both patient experience and outcomes in bone marrow transplantation. For example, this article will not delve into the use of acupuncture to re-instigate peristalsis after it stops due to Total Parenteral Nutrition (TPN), and loss of peristalsis due to TPN leads to worse outcomes.) But in the hope of opening doors and conversations about lowering the toxic burden of medications and creating better patient outcomes, it will cover a few of the ways that integrative interventions can help.

CINV in High-Dose / Myeloablative Chemotherapy

The 2000 JAMA trial by Shen et al. (one of the foundational studies in acupuncture-CINV research) was specifically conducted in patients receiving high-dose, myeloablative chemotherapy, including cyclophosphamide, cisplatin, and carmustine. The results are significant: the trial demonstrated that electroacupuncture significantly reduced emesis episodes compared to both minimal needling and pharmacotherapy alone in this most extreme chemotherapy context. Patients receiving electroacupuncture had a median of 5 emesis episodes during the study period, compared to 10 for minimal needling and 15 for pharmacotherapy alone — a clinically meaningful reduction in one of the most severe CINV contexts.³

Severe Mucositis in the BMT Setting

Mucositis in the BMT setting is qualitatively and quantitatively more severe than in standard chemotherapy. Across all BMT procedures, up to 80% of patients develop mucositis, and for some patient populations, the percentage is greater than 95%. In marrow-ablative chemotherapy-induced mucositis, sores of the inflamed mucosa extend throughout the gastrointestinal tract (including lips, mouth, tongue, esophagus, intestines, and even rectum). Developing mucositis significantly increases the risk of systemic infection during the period of maximum immune vulnerability.

‍ ‍Severe mucositis is particularly dangerous to the BMT patient receiving allogenic cells, such as patients with Diamond-Blackfan Anemia receiving entirely new marrow stem cells from an unrelated donor, due to the increased risk of GVHD. Historically, transplant physicians have regarded mucositis as “the most distressing side-effect for patients, but the one they (as physicians) worry the least about.” The reason has less to do with its impact on the patient and more to do with the fact that those in allogenic transplant face a host of extremely dangerous life-threatening complications, such as graft rejection, development of Veno-Occlusive Disease (VOD), septic infection while immunocompromised, and Thrombotic Microangiopathy (TMA). Compared to sepsis, VOD, and TMA, mucositis seems like small potatoes.

However, mucositis has greater impacts than transplant physicians may realize. Recent studies have shown that damage to gastrointestinal integrity and the loss of a robust and diverse oral and gut microbiome is a significant risk factor for the development of chronic GVHD (cGHVD). In fact, severe oral mucositis (SOM) during conditioning for allogenic hematopoietic cell transplantation (HCT) is strongly linked to an increased risk of developing cGVHD. ²⁰˒²¹

This makes the development of SOM a potentially devastating side-effect. For transplanted patients, cGVHD is effectively trading one life-threatening, life-limiting condition for another. Treatment of cGVHD involves lengthy periods of steroids and other immune suppressions, often requiring social isolation, masking, and avoidance of the sun. Hair loss, nail loss, skin changes, joint pain, changes in ability to swallow, and lung damage are all common symptoms of cGVHD. With such severe impacts on quality of life, it is no surprise that cGVHD is one of a patient’s most feared complications of transplant.

Due to the fact that mucositis has been proven to lead to worse outcomes, it is no longer acceptable for transplant physicians to disregard it as an uncomfortable, but not dangerous, side effect. It is imperative that integrative therapies that have shown a potential ability to safeguard the mucosa from damage while not affecting marrow-ablative goals be prioritized for consideration in HCT.

Immune Reconstitution: Rebuilding the System After Marrow Ablation

After allogenic BMT, the patient's immune system must be entirely rebuilt from transplanted stem cells. In effect, the new immune system is that of a newborn’s, but without the benefit of breastmilk to provide some level of acquired immune support. This reconstitution period carries significant clinical risk: opportunistic fungal, bacterial, and viral infections due to an immune system that is not fully present and functional, as well as GVHD due to an awakening immune system that may recognize its new body as “not self” and decide to attack its host. Safe immune reconstitution can take months to years to complete.

Chinese herbal medicine has documented effects on immune modulation that are relevant to this phase — but again, this is one of the places where the most clinical discernment is required. The same herbs that support immune function in a depleted but otherwise healthy person could theoretically amplify inflammatory responses in a setting where GVHD is the concern. This is not a reason to avoid herbal medicine post-BMT. It is, however, a real reason to work with a provider who understands the immunology of engraftment and can select herbs and formulas appropriate to the phase of reconstitution. Likewise, it is vital that laboratory measures are drawn and patients are monitored closely for undesirable changes.

In China, where integrative oncology is standard hospital practice for approximately 70% of cancer patients, Chinese herbal medicine has been used alongside BMT for decades.¹⁹ Research here is most developed around myelosuppression recovery. Danggui Buxue Decoction, Rehmannia glutinosa oligosaccharides and polysaccharides, and Astragalus-based formulas have demonstrated promotion of hematopoietic growth factor secretion and restoration of bone marrow hematopoietic function in both clinical and preclinical research.¹⁶˒¹⁴ Rehmannia compounds specifically promote the production of hematopoietic growth factors that accelerate marrow repopulation — a mechanism with direct relevance to engraftment support.

Again, the gut microbiome is especially important post-BMT. Chemotherapy and antibiotics used during the conditioning period profoundly deplete microbiome diversity, and the reconstituting microbiome substantially influences immune maturation and GVHD risk. Chinese herbal formulas, particularly polysaccharide-rich herbs like Astragalus and Poria, have documented prebiotic-like effects on gut microbiome diversity and beneficial bacterial populations. The research on TCM as a microbiome modulator in the cancer immunotherapy context is an emerging frontier with considerable clinical promise.¹⁸

Pulmonary and Other Organ Protection Post-BMT

High-dose conditioning chemotherapy carries increased pulmonary toxicity risks beyond those seen at standard doses, and post-transplant pulmonary complications are a significant cause of morbidity. Multiple Chinese herbal medicine compounds protect cardiac mitochondria from anthracycline toxicity, and these compounds have overlapping anti-inflammatory and antioxidant mechanisms relevant to pulmonary tissue. However, more direct clinical research on pulmonary protection in the BMT context using Chinese herbal medicine is needed. Even so, the historical clinical tradition is extensive, and the biological mechanistic rationale for Chinese herbal medicine to improve lung health and function is strong.

A Review of the Research Landscape

The body of evidence for integrative support during and after chemotherapy varies by symptom and modality. CINV has the strongest and most rigorous evidence, including a 2024 JCO randomized controlled trial. Cardio-protection from Chinese herbal medicine has strong mechanistic evidence and is promising, but is still growing clinical trial data. Mucositis, fatigue, myelosuppression, and CIPN are well-supported at the systematic review level. Pulmonary protection and immune reconstitution post-BMT are areas where the biological rationale is clear, but large-scale clinical evidence is still developing.

What is consistent across all of these areas is that no serious adverse interactions between properly prescribed Chinese herbal medicine and standard chemotherapy have been documented in the clinical research. It is also clear across all research that integrative approaches consistently address mechanisms that standard supportive care does not.

This is the clearest view of how integrative medicine can transform oncology and non-malignant transplant: not as a replacement for chemotherapy, but as the safest and most efficacious way to prevent damage to untargeted tissues from toxic agents, restore health and function of organs and tissues that were inadvertently damaged, and reduce the occurrence and severity of life-impacting complications.

Who Might Benefit from Integrative Chemotherapy Support?

An integrative consultation is appropriate for:

• Anyone currently undergoing chemotherapy who is experiencing nausea, fatigue, pain, neuropathy, mucositis, or other side effects not fully controlled by conventional supportive care

• Patients receiving anthracycline-based regimens who are concerned about cardiac effects and want to explore evidence-based herbal support

• Patients preparing for or recovering from bone marrow transplantation who want support for engraftment, gut healing, acute or chronic GVHD, and immune reconstitution

• Cancer and non-malignant transplant survivors dealing with persistent post-treatment fatigue, neuropathy, cognitive changes ("chemo brain"), or gut dysfunction

• Anyone who wants to approach treatment with the full toolkit of evidence-based support, not just what conventional oncology alone provides

At Chiyu Integrative Health, all chemotherapy and transplant support plans are developed in coordination with the patient's oncology or transplant teams. Recommendations are based on a thorough review of specific chemotherapy agents, medications, timing of treatment cycles, and individual presentation. Timing, selection, and dosing of individual herbs, nutrients, and Chinese herbal formulas requires specialized knowledge that goes beyond informal herbal practice. This is not self-prescription territory — it requires precision, careful laboratory monitoring, and modification as the condition changes.

About the Author

Dr. Erika F. Marie, DACM is a Doctor of Acupuncture and Chinese Medicine, West Point graduate, and founder of Chiyu Integrative Health. She is a published researcher in and peer-reviewer for EXPLORE: The Journal of Science and Healing. Dr. Marie has direct experience supporting patients through complex cancer treatment, including her daughter's successful bone marrow transplant for a rare blood disorder using an integrative approach alongside conventional care. She consults with patients in-person in Colorado or South Carolina and by phone or video.

Ready to Explore Integrative Support?

You do not have to choose between conventional and integrative care — time and again, it has been proven that they work best together. A thorough assessment will identify which interventions are appropriate, safe, and well-timed relative to your specific treatment protocol.

Schedule a phone consultation by calling (720) 213-4999. Learn more at chiyuintegrativehealth.com‍. ‍For more articles like this about other conditions we treat, visit our research page.

References

1. Yan Y, López-Alcalde J, Zhang L, Siebenhüner AR, Witt CM, Barth J. Acupuncture for the prevention of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis. Cancer Medicine, 2023;12:12504–12517. University of Zurich. PMC10278514. https://pmc.ncbi.nlm.nih.gov/articles/PMC10278514/

2. Shen G, Ren D, Zhao F, et al. Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial. Journal of Clinical Oncology. 2024;42(34):4051–4059. doi: 10.1200/JCO.24.00099. https://ascopubs.org/doi/abs/10.1200/JCO.24.00099

3. Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: A randomized controlled trial. JAMA. 2000;284:2755–2761. PubMed ID: 11105182. https://pubmed.ncbi.nlm.nih.gov/11105182/

4. Effectiveness and Safety of Acupuncture for Nausea and Vomiting in Cancer Patients: A Systematic Review and Meta-Analysis — databases through December 2024, 17 RCTs; vagal-adrenal axis mechanism (Nature citation). MDPI Medicine, 2025. PMC12300855. https://pmc.ncbi.nlm.nih.gov/articles/PMC12300855/

5. The Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Meta-Analysis — serotonergic/5-HT3 mechanism for oxaliplatin-induced CINV confirmed. PMC7242803. https://pmc.ncbi.nlm.nih.gov/articles/PMC7242803/

6. Acupuncture in cancer-related fatigue — systematic review and meta-analysis; HPA axis normalization, cytokine reduction, opioid release, sleep quality mechanisms. Cited in: Treatment of Cancer-Related Symptoms, multiple systematic reviews. See also: PMC12300855.

7. Xie Y, Fang X, Hua H, Zhou P. Efficacy and Safety of Chinese Patent Medicine for the Prevention and Treatment of Radiotherapy and Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022;13:812085. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.812085/full

8. Zhang W, Fan L, Xie Y, Gao T, Zeng J. Clinical efficacy and applicability of natural products in the treatment and prevention of radiotherapy-induced oral mucositis: A systematic review. PLOS ONE. 2024;19(5):e0303988. PubMed ID: 38781255. https://pubmed.ncbi.nlm.nih.gov/38781255/

9. Meyer-Hamme G, Rostock M, Bröring R, Schröder S. A survey of Chinese medicinal herbal treatment for chemotherapy-induced oral mucositis — 18 studies, 4 single herbs, 11 multi-herb prescriptions; 96.7% vs 86.7% improvement rates; molecular mechanisms including ROS reduction, IL-6 suppression, wound healing. PMC3830834. https://pmc.ncbi.nlm.nih.gov/articles/PMC3830834/

10. Efficacy and Safety of Acupuncture in Managing Radiotherapy/Chemotherapy-Induced Oral Mucositis: A Systematic Review and Meta-Analysis — 8 biomedical databases through July 2025. Supportive Care in Cancer, 2025. https://link.springer.com/article/10.1007/s00520-025-09931-7

11. Chemotherapy cardiotoxicity bibliometric and visual analysis — electroacupuncture at PC6 prevents doxorubicin cardiotoxicity via nitric oxide reduction; TCM cardioprotective overview. PMC12119586. https://pmc.ncbi.nlm.nih.gov/articles/PMC12119586/

12. Cardioprotective effect of Chinese herbal medicine for anthracycline-induced cardiotoxicity in cancer patients: A meta-analysis of 17 RCTs of 11 CHMs — effective and safe cardioprotective intervention. Medicine. 2022;101(30):e29691. https://journals.lww.com/md-journal/fulltext/2022/07290/cardioprotective_effect_of_chinese_herbal_medicine.55.aspx

13. Natural Compounds from TCM Against Doxorubicin-Induced Cardiotoxicity — 104 preclinical studies, 65 compounds, 6 core pathways; Nrf2, SIRT1, mTOR, AMPK as hub nodes; Salvia miltiorrhiza, Astragalus, ginsenosides. Basic & Clinical Pharmacology & Toxicology, 2026. https://onlinelibrary.wiley.com/doi/10.1111/bcpt.70228

14. Chinese herbal medicine for myelosuppression induced by chemotherapy or radiotherapy: systematic review of RCTs — CHM significantly protected WBCs from chemotherapy damage. PMC4352943. https://pmc.ncbi.nlm.nih.gov/articles/PMC4352943/

15. Validated herbal extracts for alleviating chemotherapy-induced myelosuppression: Systematic review and meta-analysis — 6 databases, evidence supporting hematopoietic recovery. PubMed ID: 40220426. https://pubmed.ncbi.nlm.nih.gov/40220426/

16. Danggui Buxue Decoction alleviates cyclophosphamide-induced myelosuppression via β-hydroxybutyric acid metabolism and oxidative stress suppression — blood cell counts upregulated 118–243%. Pharm Biol. 2023. PubMed ID: 37096658. https://pubmed.ncbi.nlm.nih.gov/37096658/

17. Acupuncture for postoperative gastrointestinal dysfunction in colorectal cancer — systematic review and meta-analysis; vagal modulation, enteric serotonin, anti-inflammatory gut wall mechanisms. Cited in: IntechOpen Colorectal Cancer Chapter, 2025. https://www.intechopen.com/online-first/1226625

18. Applications of TCM in cancer immunotherapy via gut microbiota modulation — Akkermansia muciniphila enrichment, SCFA restoration, immune cell modulation, ICI synergy. ScienceDirect, 2025. https://www.sciencedirect.com/science/article/pii/S1043661825004451

19. TCM utilized in approximately 70% of cancer patients in China — synergism with chemotherapy, bone marrow suppression, immune regulation. PMC11734505. https://pmc.ncbi.nlm.nih.gov/articles/PMC11734505/

20. Yui Kambara, Hideaki Fujiwara, Akira Yamamoto, Kazuyoshi Gotoh, Shuma Tsuji, Mari Kunihiro, Tadashi Oyama, Toshiki Terao, Ayame Sato, Takehiro Tanaka, Daniel Peltier, Keisuke Seike, Hisakazu Nishimori, Noboru Asada, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, Ken-ichi Matsuoka, Yoshihiko Soga, Pavan Reddy, Yoshinobu Maeda; Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease. Blood 2025; 145 (8): 881–896. doi: https://doi.org/10.1182/blood.2024024540

21. Vinicius Campos de Molla, Vitor Heidrich, Julia Bruno, Franciele Knebel, Wanessa Miranda-Silva, Paula Asprino, Luciana Tucunduva, Vanderson Rocha, Yana Novis, Anamaria Camargo, Eduardo Fregnani, Celso Arrais-Rodrigues; Disruption of the Oral Microbiota Predicts Poor Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 2020; 136 (Supplement 1): 44–45. doi: https://doi.org/10.1182/blood-2020-135937

Disclaimer: This article is for educational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation. Always consult your oncologist and a qualified integrative medicine practitioner before beginning any herbal therapy during or after cancer or chemotherapy treatment. Some herbs are contraindicated with specific chemotherapy agents or during particular phases of bone marrow transplantation. Herb-drug interactions require professional screening.‍ ‍